Detalhe da pesquisa
1.
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.
N Engl J Med
; 388(1): 44-54, 2023 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546659
2.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658005
3.
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Future Oncol
; 18(6): 639-647, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911336
4.
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer
; 126(2): 432-443, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581306
5.
Adagrasib in Non-Small-Cell Lung Cancer. Reply.
N Engl J Med
; 387(13): 1238-1239, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-36170509
6.
A review of canakinumab and its therapeutic potential for non-small cell lung cancer.
Anticancer Drugs
; 30(9): 879-885, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31503012
7.
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.
Lancet Oncol
; 18(8): 1061-1075, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28645776
8.
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review.
JCO Precis Oncol
; 8: e2300644, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38579193
9.
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.
J Clin Oncol
; : JCO2301909, 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38652877
10.
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
Nat Med
; 30(4): 1013-1022, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538867
11.
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Invest New Drugs
; 31(5): 1330-8, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23761052
12.
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
J Clin Oncol
; 41(28): 4472-4477, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37327468
13.
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.
J Clin Oncol
; 41(25): 4097-4106, 2023 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099736
14.
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.
J Clin Oncol
; 41(26): 4218-4225, 2023 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37384848
15.
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
Clin Cancer Res
; 29(16): 3074-3080, 2023 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37279096
16.
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
J Thorac Oncol
; 18(8): 1094-1102, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37146752
17.
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer.
Front Oncol
; 13: 1215524, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37700839
18.
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.
Expert Rev Anticancer Ther
; 23(1): 95-106, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36537204
19.
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
J Thorac Oncol
; 18(7): 907-921, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36842467
20.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Nat Med
; 29(10): 2577-2585, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37710001